Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity

Open access
Ali, Simak, Heathcote, Dean A., Kroll, Sebastian H.B., Jogalekar, Ashutosh S., Scheiper, Bodo, Patel, Hetal, Brackow, Jan, Siwicka, Alekasandra, Fuchter, Matthew J., Periyasamy, Manikandan, Tolhurst, Robert S., Kanneganti, Seshu K., Snyder, James P., Liotta, Dennis C., Aboagye, Eric O., Barrett, Anthony G.M., Coombes, R. Charles·2009·Cancer Research

Abstract

Normal progression through the cell cycle requires the sequential action of cyclin-dependent kinases CDK1, CDK2, CDK4, and CDK6. Direct or indirect deregulation of CDK activity is a feature of almost all cancers and has led to the development of CDK inhibitors as anticancer agents. The CDK-activating kinase (CAK) plays a critical role in regulating cell cycle by mediating the activating phosphorylation of CDK1, CDK2, CDK4, and CDK6. As such, CDK7, which also regulates transcription as part of the TFIIH basal transcription factor, is an attractive target for the development of anticancer drugs. Computer modeling of the CDK7 structure was used to design potential potent CDK7 inhibitors. Here, we show that a pyrazolo[1,5-a]pyrimidine–derived compound, BS-181, inhibited CAK activity with an IC50 of 21 nmol/L. Testing of other CDKs as well as another 69 kinases showed that BS-181 only inhibited CDK2 at concentrations lower than 1 μmol/L, with CDK2 being inhibited 35-fold less potently (IC50 880 nmol/L) than CDK7. In MCF-7 cells, BS-181 inhibited the phosphorylation of CDK7 substrates, promoted cell cycle arrest and apoptosis to inhibit the growth of cancer cell lines, and showed antitumor effects in vivo. The drug was stable in vivo with a plasma elimination half-life in mice of 405 minutes after i.p. administration of 10 mg/kg. The same dose of drug inhibited the growth of MCF-7 human xenografts in nude mice. BS-181 therefore provides the first example of a potent and selective CDK7 inhibitor with potential as an anticancer agent. [Cancer Res 2009;69(15):6208–15]

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-09-0301

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 161

Metadata

Authors
Ali, S., Heathcote, D. A., Kroll, S. H. B., Jogalekar, A. S., Scheiper, B., Patel, H., Brackow, J., Siwicka, A., Fuchter, M. J., Periyasamy, M., Tolhurst, R. S., Kanneganti, S. K., Snyder, J. P., Liotta, D. C., Aboagye, E. O., Barrett, A. G. M., & Coombes, R. C.
Venue
Cancer Research
Published
2009-07-29
Volume
69
Issue
15
Pages
6208-6215
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2120856107
Cited by
161
References
4
FWCI
2.39
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity. https://app.cochat.ai/papers/10.1158/0008-5472.can-09-0301
The paper
Ali, S., Heathcote, D. A., Kroll, S. H. B., Jogalekar, A. S., Scheiper, B., Patel, H., Brackow, J., Siwicka, A., Fuchter, M. J., Periyasamy, M., Tolhurst, R. S., Kanneganti, S. K., Snyder, J. P., Liotta, D. C., Aboagye, E. O., Barrett, A. G. M., & Coombes, R. C. (2009). The Development of a Selective Cyclin-Dependent Kinase Inhibitor That Shows Antitumor Activity. Cancer Research. https://doi.org/10.1158/0008-5472.can-09-0301

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.